BELLEVUE, Wash., Nov. 21, 2017 -- Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTCQB:VPLM) is pleased to announce that final decisions in the two Apple IPRs, IPR2016-01201 and IPR2016-01198, have confirmed the patentability of all challenged claims. Additionally, institution has been denied in the three AT&T IPR petitions, IPR2017-01382, IPR2017-01383, and IPR2017-01384, and the two Apple follow-on petitions IPR2017-01398 and IPR2017-01399. These decisions from the Patent Trial and Appeal Board will be posted on the Company’s website www.voip-pal.com.
Emil Malak, CEO of Voip-Pal, stated, “This has been an extremely difficult 18-month long ordeal for our Company while we have been working diligently to successfully defend our patents against eight IPR petitions. We are fortunate to have the best technical and legal teams supporting us during this process. We are also extremely grateful to be represented by the best intellectual property attorneys, Knobbe Martens, who have stuck with us every step of the way for nearly eight years. We appreciate the support of our loyal shareholders during this difficult process.”
“Our strategy remains to pursue an amicable settlement in order to achieve monetization of our patent portfolio; we will keep everyone informed of our progress.”
“We would also like to wish our shareholders a very happy and healthy Thanksgiving.”
About Voip-Pal.com Inc.
Voip-Pal.Com, Inc. (“Voip-Pal”) is a publicly traded corporation (OTCQB: VPLM) headquartered in Bellevue, Washington. The Company owns a portfolio of patents relating to Voice-over-Internet Protocol (“VoIP”) technology that it is currently looking to monetize.
Corporate Website: www.voip-pal.com
IR inquiries: [email protected]
IR Contact: Rich Inza (954) 495-4600


Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



